ArticleFrontiers in public health2025
The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Beyond [BMC cancer · 2026Pooled it
- Prostate cancer screening and associated factors in Ethiopia: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Burden and Trends of Genitourinary Cancers Across the Americas: A GBD 2023 Analysis of Regional Socioeconomic Gradients.Cancers · 2026Article
- Clinicopathological Profile of Prostate Cancer Patients at a Tertiary Hospital in the Eastern Cape, South Africa.International journal of environmental research and public health · 2026Article
- In Vitro Antiproliferative Effects of Benzothiazole-Based Aminosquaraine Dyes Against Cancer Cell Lines.Molecules (Basel, Switzerland) · 2026Article
- Early Postoperative Outcomes with the ToumaiCancers · 2026Article
- Uncovering Time-DependentMolecules (Basel, Switzerland) · 2026Article
- EBF1 Deficiency Drives Prostate Cancer Progression by Interfering with the Transcriptional Regulation ofOncology research · 2026Article
- Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.Drug design, development and therapy · 2026Article
- Sex differences in global burden of Congenital Heart Anomalies in children under five from 1990 to 2021.PloS one · 2026Article
- Awareness, risk perception, and attitudes toward prostate cancer detection and MRI among Armenian men.Frontiers in public health · 2026Article
- Androgen Effects on Amyloid Precursor Protein Processing Pathways in Cancer: A Systematic Review.Current issues in molecular biology · 2025Review
- Application Effect of Different Robotic Surgery Systems in Radical Prostatectomy: A Comparative Study Based on a Network Meta-analysis.European urology open science · 2025Review
- Global trends in prostate cancer burden among adults aged 80 years and older from 1990 to 2021 based on the global burden of disease 2021.Discover oncology · 2025Article
- Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes.International journal of molecular sciences · 2025Review
- Psychological Involvement in the Journey of a Patient with Localized Prostate Cancer-From Diagnosis to Treatment.Diseases (Basel, Switzerland) · 2025Article
- Unmasking Elevated PSA: Prevalence and Modifiable Risk Factors in Men Aged ≥ 40 Years Attending Kabutare District Hospital in Rwanda.Research and reports in urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising annual incidence of prostate cancer (PCa) has become a significant health challenge for men worldwide. The study aims to estimate the contemporary disease burden of PCa across global, regional, and national levels. Methods: Data from the Global Burden of Disease Study 2021 (GBD 2021) was analyzed to evaluate trends in PCa incidence, prevalence, disability-adjusted life years (DALYs), and mortality from 1990 to 2021. Determinants of PCa burden were investigated through Spearman correlation analysis with socio-demographic index (SDI), decomposition analysis, and frontier analysis to assess regional improvement potential. Results: In 2021, global PCa incidence reached 1.32 million cases [95% uncertainty interval (UI): 1217320.93, 1400222.17]. Between 1990 and 2021, the global estimated annual percentage change (EAPC) of age-standardized incidence rates (ASIR), prevalence rates (ASPR), DALYs rates (ASDR), and mortality rates (ASMR) were declined or increased at -0.06% [95% confidence interval (CI): -0.21, 0.08], 0.42% (95% CI: 0.26, 0.58), -0.96% (95% CI: -1.05, -0.87), and -0.58% (95% CI: -0.73, -0.44), respectively. Low-middle SDI countries exhibited the steepest rate increases, with males over 50 years being most affected. Significant positive correlations emerged between SDI levels and ASIR ( Conclusion: Our findings demonstrated that despite modest declines in ASDR and ASMR within high SDI regions, PCa burden metrics persistently increased in low-middle SDI quintiles. Nations across all development levels require urgent implementation of evidence-based policies and precision management strategies to mitigate this growing public health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.